Comparison · NCT00715208-38499e2b
VELCADE R-CAP vs VELCADE R-CP: Number of Participants With Overall Response (OR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. VELCADE R-CAP vs VELCADE R-CP: Number of Participants With Overall Response (OR). Trial comparisons, record NCT00715208-38499e2b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00715208-38499e2b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.61 | 1 | wilson | |
| Risk in group 2 | 0.771 | 0.635 | 0.867 | wilson | |
| Risk difference, group 1 minus group 2 | 0.229 | -0.173 | 0.365 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.3 | 1.11 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on VELCADE R-CAP than on VELCADE R-CP | 4.36 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | VELCADE R-CAP | VELCADE, rituximab, cyclophosphamide, prednisone, and Doxorubicin | 6 | 6 | OG000 |
| Group 2 | VELCADE R-CP | VELCADE, rituximab, cyclophosphamide, and prednisone | 37 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Overall Response (OR)
- Description
OR = Complete Response (CR) + Partial Response (PR)according to the revised International Working Group (IWG) Criteria.~CR is the disappearance of all evidence of disease assessed by CT and PET. PR is the regression of measurable disease and no new sites assessed by CT and PET.
- Time frame
- 30 weeks
- Population
- Response evaluable: measurable disease at baseline, completed first scheduled response evaluation, or do not complete first scheduled response evaluation due to PD or death.
Source ClinicalTrials.gov
Trial
- Title
- Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
- NCT number
- NCT00715208
- Phases
- PHASE2
- Conditions
- Relapsed Follicular Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin, VELCADE, prednisone
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Results first posted
- 2013-04-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00715208?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00715208-38499e2b